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Abstract
Objective: To study the position of hemiplegic migraine in the clinical spectrum of migraine with aura and to reveal the
importance of CACNA1A, ATP1A2 and SCN1A in the development of hemiplegic migraine in Finnish migraine families.
Methods: The International Classification of Headache Disorders 3rd edition criteria were used to determine clinical
characteristics and occurrence of hemiplegic migraine, based on detailed questionnaires, in a Finnish migraine family
collection consisting of 9087 subjects. Involvement of CACNA1A, ATP1A2 and SCN1A was studied using whole exome
sequencing data from 293 patients with hemiplegic migraine.
Results: Overall, hemiplegic migraine patients reported clinically more severe headache and aura episodes than non-
hemiplegic migraine with aura patients. We identified two mutations, c.1816G>A (p.Ala606Thr) and c.1148G>A
(p.Arg383His), in ATP1A2 and one mutation, c.1994C>T (p.Thr665Met) in CACNA1A.
Conclusions: The results highlight hemiplegic migraine as a clinically and genetically heterogeneous disease. Hemiplegic
migraine patients do not form a clearly separate group with distinct symptoms, but rather have an extreme phenotype in
the migraine with aura continuum. We have shown that mutations in CACNA1A, ATP1A2 and SCN1A are not the major
cause of the disease in Finnish hemiplegic migraine patients, suggesting that there are additional genetic factors con-
tributing to the phenotype.
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Introduction
Hemiplegic migraine (HM) is a rare and severe subtype
of migraine with aura. It is characterized by fully
reversible and unilateral motor weakness (hemiparesis),
but otherwise it has similar clinical features as migraine
with aura (1). Familial hemiplegic migraine (FHM) is
diagnosed when there is at least one ﬁrst- or second-
degree relative in the family with HM, otherwise spor-
adic hemiplegic migraine (SHM) is diagnosed, while
both share similar clinical characteristics (1,2). Severe
attacks may occur in both forms with prolonged hemi-
plegia, confusion, coma, fever, and CSF pleocytosis.
The clinical spectrum may also include permanent cere-
bellar signs (nystagmus, ataxia, dysarthria) and less fre-
quently epilepsy (1).
FHM has been suggested to be a monogenic, genet-
ically heterogeneous channelopathy disorder, with
three deﬁnite causative genes, CACNA1A (FHM1)
(3), ATP1A2 (FHM2) (4), and SCN1A (FHM3) (5).
Despite their role in individual families with several
aﬀected family members, mutations in these three
genes do not seem to be the major cause of HM in
the general population (6,7), suggesting additional
causal or contributing variants/genes for HM. A few
other genes have been suggested, but their causality
has not been conﬁrmed (8).
This study is part of the Finnish Migraine Genome
Project, a large ongoing family study focusing on clin-
ical and genetic aspects of migraine. Here, we investi-
gate the clinical characteristics and occurrence of HM
in Finnish migraine families and study the involvement
of CACNA1A, ATP1A2 and SCN1A in HM.
Furthermore, we compare the clinical and genetic char-
acteristics of this questionnaire-based family sample to
previous population and clinical-based studies on hemi-
plegic migraine.
Material and methods
Patients
All participants gave informed consent, and
approval to conduct the research was obtained
from the Ethics Committee of the Hospital District
of Helsinki and Uusimaa (111/13/03/01/2011,
3.8.2011).
The Finnish Migraine Genome Project is a large
ongoing family study. It was initiated in 1992 focusing,
at ﬁrst, on migraine with aura families. Migraine
patients and their relatives are recruited from headache
clinics around Finland (primarily from Helsinki,
Turku, Tampere, Jyva¨skyla¨, Kuopio and Kemi) and
the Finnish Migraine Association. The participants
are asked to ﬁll out the validated Finnish Migraine-
Speciﬁc Questionnaire for Family Studies (9) and to
donate a blood sample for genetic studies. In addition,
the index patients are clinically examined. Genomic
DNA is extracted from peripheral blood cells with
standard protocols.
By July 2014, 9087 migraine patients and their family
members had taken part in the study (Figure 1).
Altogether, 3383 subjects fulﬁlling the criteria for
migraine with aura were included in this study. Of
these, 406 patients had experienced two or more migraine
attacks with fully reversible motor weakness and thus
formed the hemiplegic migraine group (HM-group).
The rest of the patients (n¼ 2977) formed the non-hemi-
plegic migraine with aura group (NHMwA-group)
(Figure 1). All diagnoses were based on the criteria of
the International Classiﬁcation of Headache Disorders,
3rd edition, beta version (ICHD-3 beta criteria) (1).
According to the ICHD-3 beta, 131 patients were
diagnosed with FHM and 275 patients with SHM.
SHM patients had a diverse familial background for
migraine, including third-degree or more distant rela-
tives with HM and closer relatives with other subtypes
of migraine. Altogether 24% of the SHM families had
more than ﬁve family members with migraine with or
without aura in addition to the SHM cases (Figure 2).
Seventy-two patients with HM were classiﬁed as SHM
due to unknown family history for migraine.
The 131 FHM patients belonged to 51 families. Most
families had two (n¼ 32) or three (n¼ 12) FHM
patients, while there were seven families with more
than three FHM patients. Most of the families (94%)
also contained members diagnosed with migraine with
aura and/or migraine without aura (Figure 2).
Statistical methods
The HM and NHMwA groups were compared
for 59 clinical variables related to migraine headache,
migraine aura and migraine comorbidities.
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Within the study, all anamnestic data of seizures
(also febrile seizures), any epileptic activity and
sudden loss of consciousness, were classiﬁed as parox-
ysmal symptoms.
Statistical analyses were performed using IBM SPSS
Statistics 22.0.0.0. In order to determine association
of nominal variables across patient groups, Fisher’s
Exact test was used for 2 2 tables, while Pearson’s
Finnish migraine family cohort
n=9087 (by July 2014)
Patients with other migraine subtypes
and unaffected family members
n=5704
Patients with MwA
n=3383
Clinical analysis
Genetic analysis
Variant filtering step 1
Variant filtering step 2
Interpretation
HM subgroup NHMwA Subgroup
n=406
(from 321 families)
131 FHM patients
(from 51 families)
92 FHM patients
(from 44 families) Exome sequencing datafrom 293 HM patients
(from 243 families)
275 SHM patients
(from 270 families)
201 SHM patients
(from 199 families)
Clinical
10 samples failed quality control
27 variants
9 variants
12 false variantsValidation by
sanger sequencing
Screening of CACNA1A,
ATP1A2 and SCN1A
Family with the known ATP1A2
mutation p.Thr345Ala*
comparison
n=2977
- MAF in gnomAD < 0.01
- MAF in Finns < 0.001 (SISu)
- SIFT and PolyPhen2
- Paralog conservation score
- Co-segregation
- Literature
5 likely
benign variants
- Consequence based on VEP
3 pathogenic variants 1 probable
causative variant
p.Ser2501Ter (CACNA1A)
p.Thr665Met (CACNA1A)
p.Arg383His (ATP1A2)
p.Ala606Thr (ATP1A2)
Figure 1. Flowchart of the clinical and genetic analyses. MwA: migraine with aura; HM: hemiplegic migraine; FHM: familial hemiplegic
migraine; SHM: sporadic hemiplegic migraine; NHMwA: non-hemiplegic migraine with aura; MAF: minor allele frequency; gnomAD:
The Genome Aggregation Database; SISu: The Sequencing Initiative Suomi Database; VEP: the Variant Effect Predictor; SIFT (Sorts
Intolerant From Tolerant) and PolyPhen2 (Polymorphism Phenotyping v2): variant prioritization tools.
*FHM family with a previously identified mutation (p.Thr345Ala) in ATP1A2 gene (12).
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Chi-Square test was used for larger tables.
The Mann-Whitney U test was used for comparing
means. Missing data were excluded from the analyses
(see Supplementary tables 1–3 for response rate
details). All reported p-values are two-sided and not
corrected for multiple testing. Results with p< 0.05
were considered as evidence of signiﬁcant diﬀerences
between the groups, though the plausibility of type I
Gender distribution
Daily
Every other day
Weekly
Monthly
Less frequently
Almost never
<4 hours
Pulsatile
Mild
Moderate
Severe
Unbearable
Nausea***
Vomiting***
Photophobia***
Phonophobia***
Sensitivity to odors***
After images***
Unilateral***
Side-switching***
Headache prevents working***
Phhysical activity worsens headache***
4–72 hours
>72 hours
Headache frequency at the time of filling the questionnaire***
Headache characteristics
Headache intensity***
Coexisting symptoms
Typical headache duration without medication***
Percentage of women*** 75%
5%
3%
8%4%
36%
29%
25%
28%
25% 33%
10% 21%
75%
72%
85%
69%
52%
38%
68%63%
50%
30%
91%
83%
2%
8%
22%
32%
45%
43%
30%
17%
94%84%
74%55 %
99%
91%
92%
77%
86%
67%
66%46%
(*) P < 0.05, (**) P < 0.01, (***) P < 0.001
15%
7%
0%
3%
86%
HM
NHMwA
Figure 3. Characteristics of headache in hemiplegic migraine (HM) patients compared to non-hemiplegic migraine with aura
(NHMwA) patients.
% in SHM families
(n=270)
% in FHM families
(n=51)
Number of family members having migraine with or without aura 0 1–2 3–4 ≥5
27% 30% 19% 24%
68%10%16%6%
Figure 2. Migraine load in the studied families. SHM: sporadic hemiplegic migraine; FHM: familial hemiplegic migraine.
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errors should be kept in mind while interpreting the
results.
We applied explorative principal components ana-
lysis (PCA) (10) to the clinical variables listed in
Figure 3, Figure 4 and Figure 5, excluding the HM-
speciﬁc symptoms (four related to motor weakness
and two to clumsiness) from this analysis. All inspected
53 phenotypes were coded into 75 dichotomous dummy
variables. After removing 653 individuals (24 HM
cases) having 50% or more missing answers, the
remaining missing answers were interpreted as no-
answers. The ﬁnal PCA data consisted of 2730 individ-
uals (382 HM cases). To identify the number of relevant
PCA components, we used Horn’s parallel analysis (10),
Visual aura HM
NHMwA
Duration of visual aura***
Headache and visual aura
Other aura symptoms
Motor weakness
Unilateral motor weakness
4-limb motor weakness
Face
Upper limb
Lower limb
Hemisensory symptom***
4-limb sensory symptom***
Oral sensory symptom***
Basilar vertigo***
Other dizziness***
Clumsiness of hands or objects keep falling from hands***
Clumsiness of legs or issues with balance***
Tinnitus***
Hypocusia (decreased hearing)***
Ear ache*
Ear pressure sensation***
Visual disturbance in both eyes*
Diplopia (double vision)***
Swallowing difficulties***
Tongue stiffness or numbness***
Pharyngeal numbness***
Fainting or unconsciousness***
Fever***
Disorientation or confusion***
Nasal congestion***
Lacrimation***
Eyelid swelling
Motion sickness
Eye turns red**
Hands turn easily white in cold temperatures***
Speech disturbance***
Motor weakness localisation
Basilar symptoms
Other symptoms
Visual aura presents with headache***
Scotoma***
<1 min
Headache follows visual aura in ≤60 min
Headache follows visual aura in >60 min
Headache and visual aura start at the same time
Headache precedes visual aura
Never
Once in a while
In half of the attacks
Very often
In all of the attacks
1–5 min
5 min–1 h
>1 h
Scintillating scotoma***
Photopsia***
Blurring vision*
Visual symptoms worsen or expand for more than 4 minutes*
(*) P < 0.05, (**) P < 0.01, (***) P < 0.001
74%51% 70%
78%
50%
51%
38%
34%
3%
6% 14%
19%
19%
9%
65%
66%
66%
63%18%
17%
1%
2%
0%
3% 18% 34%
12%
11%
31%24%
29% 38%
88%
100%
17%
75%
96%
64%
38%
13%2%
19% 80%
89%
32%
32%
38%
19%
22%
29%
82%
64%20%
28%17%
27%8%
8%4%
18%11%
51%
44%
27%15%
22%5%
68%14%
24%
16%
3%
5%
8%
2% 36%
11%
27%
28%15%
14%5%
3%7%
4%
47%
51%32%
48%
99%
14%
18%
73%
67%
Figure 4. Characteristics of aura in hemiplegic migraine (HM) patients compared to non-hemiplegic migraine with aura (NHMwA)
patients.
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which compares eigenvalues from the observed data with
eigenvalues of simulated data of the same size.
We illustrated the correlation structure of individual
migraine characteristics using polychoric correlations
(10). Polychoric correlations are a common way to
assess correlations in self-report instruments such as
health questionnaires having items with a small
number of response options. To further group related
symptoms, hierarchical clustering was conducted using
Ward’s agglomerative method (11). It is based on sum-
of-squares criterion and produces groups by progres-
sively merging similar observations together.
Whole exome sequencing (WES)
Sample selection. From the 406 HM patients, 303 DNA
samples were sent for whole exome sequencing (WES).
Individuals were selected based on a) their neurological
motor symptoms (hemiplegia or hemiparesis) and b)
the family structure. From each FHM family, the clin-
ically examined index patient and one to three add-
itional aﬀected relatives were chosen. Of the 51 FHM
families included in the clinical analysis, there are seven
families from which we do not have WES data. These
include one large FHM family with a previously iden-
tiﬁed mutation (p.Thr345Ala) in the ATP1A2 gene (12)
that was intentionally excluded from the WES analysis,
ﬁve families from which no DNA samples were avail-
able, and one family from which the sequencing failed.
Thus, sequencing results were successfully obtained
from 293 subjects (92 FHM and 201 SHM patients)
from 243 families (44 FHM and 199 SHM) (Figure 1).
Exome sequencing. WES was performed at the Wellcome
Trust Sanger Institute (Hinxton, Cambridge, UK)
throughout the years 2010–2013, using the SureSelect
Human All Exon 50Mb capture protocol (Agilent
Technologies, Santa Clara, CA, USA) and the HiSeq
next-generation sequencing system (Illumina, San
Diego, CA, US). The sequence data were aligned to
the human reference genome, NCBI Build 37
(GRCh37/hg19; The Genome Reference Consortium),
and variants were jointly called and ﬁltered together
with 10142 Finnish exomes as part of the Sequencing
Initiative Suomi (SISu) project (13). Variant calling was
performed at the Broad Institute of Harvard and MIT,
and quality control at the Institute for Molecular
Medicine Finland (FIMM).
Variant filtering. We performed variant analysis for vari-
ants in CACNA1A, ATP1A2 and SCN1A (Figure 1).
The average sequencing depth (DP) across the genes
was 26 for CACNA1A, 33 for ATP1A2 and 36 for
SCN1A. Variants were ﬁltered in a step-wise manner
to identify alterations that were rare (minor allele fre-
quency< 0.01) in the Genome Aggregation Database
(gnomAD) (14) and functionally likely to be damaging
(missense, splicing, stop gain, stop loss, in-frame inser-
tion, in-frame deletions or frameshift) based on the
Variant Eﬀect Predictor (VEP) annotations (Ensembl
Release 75) (15). Annotations were based on the
Ensembl database’s canonical transcripts: ENST00000
360228.5 (CACNA1A), ENST00000361216.3
(ATP1A2) and ENST00000303395.4 (SCN1A).
In the second ﬁltering step (Figure 1), we considered
only variants that are very rare or absent in the Finnish
population (MAF< 0.001 in the SISu database) to be
potential causal mutations. Furthermore, to interpret
the causality, we utilized SIFT (Sorts Intolerant From
Tolerant) (16) and PolyPhen2 (Polymorphism
Phenotyping v2) (17) prediction algorithms, paralog
conservation score calculations (18), co-segregation
analyses and previously published literature. The
SIFT and PolyPhen2 tools were used to predict the
pathogenicity of missense variants and paralog conser-
vation scores (para_zscore) to evaluate conservation of
the amino acid within the gene family. Missense vari-
ants that have positive paralog conservation scores
Comorbidities
Stroke
Epilepsy
Diabetes mellitus
Allergy***
Asthma*
Raynaud’s phenomenon***
Psychological disorder**
8%
8%
3%
2%
24%
18%
4%
5%
45%
(*) P < 0.05, (**) P < 0.01, (***) P < 0.001
35%
HM
NHMwA
13%
9%
22%
14%
Figure 5. Comorbidities in patients with hemiplegic migraine (HM) compared to non-hemiplegic migraine with aura (NHMwA)
patients.
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(para_zscore> 0), resulting in changes in highly con-
served amino acid residues, are more likely to be
deleterious.
Validation. Validation of candidate variants and study-
ing co-segregation in family members were done by
Sanger sequencing (FIMM Sequencing Unit, Helsinki,
Finland). Primers were designed with Primer-BLAST
(19) and sequences were analyzed using Sequencher
(Gene Codes Corporation, Ann Arbor, MI, US).
Primer sequences and PCR conditions are available
from the authors on request.
Control allele frequency databases. Allele frequency infor-
mation speciﬁc to the Finnish population was obtained
from the SISu project (13). Because the individuals stu-
died here are included in the SISu (and thus also in the
gnomAD project (14) we needed to exclude our samples
from the SISu dataset. Because we could not do the
same with the gnomAD database, we excluded all
Finnish samples from the allele frequency calculations.
In Table 1, all variant sites that were covered in <80%
of the sequenced individuals in gnomAD or SISu data-
bases are indicated by NR (not reliably estimated). Low
coverage may indicate that the genomic area is diﬃcult
to sequence and, consequently, unreliable population
frequency estimation.
Results
Clinical characteristics
Clinical characteristics of the 406 studied HM patients
are described in Figure 3, Figure 4, and Figure 5. HM
patients were younger (42.6, SD 14.0) than NHMwA
patients (47.6, SD 16.7, p< 0.001) and a higher pro-
portion of them were women (85.7% vs. 75.0%,
p< 0.001). Furthermore, HM patients reported earlier
age at onset of headache, with median of 12 years com-
pared to NHMwA patients with median of 14 years
(IQR 9–17 and 10–20 years respectively; p< 0.001,
response rate for HM 84.7% and NHMwA 67.8%).
According to ICHD-3 beta criteria, HM patients
reported more severe headache characteristics com-
pared to NHMwA patients (Figure 3). For example,
at the time of ﬁlling the questionnaire, they reported
having daily or almost daily headache more often than
NHMwA patients (12.7 vs. 6.5%, p< 0.001).
Furthermore, they had unbearable headache (30.0 vs.
17.1%), work-preventing headache (49.7 vs. 30.2%),
and headaches lasting over 72 hours (15.4 vs. 7.0%)
more often than NHMwA patients (p< 0.001). HM
patients also experienced nausea and vomiting more
often, as well as light, smell and sound sensitivity com-
pared to NHMwA patients (p< 0.001). The only
headache characteristic that was not signiﬁcantly diﬀer-
ent between the patients’ groups was the prevalence of
pulsation (Figure 3).
In addition to headache characteristics, aura epi-
sodes were also more severe in HM patients com-
pared to NHMwA patients (Figure 4). Almost all
patients reported visual disturbances, but a higher
proportion of attacks involved visual symptoms in
HM patients than in NHMwA patients (68.2 vs.
52.7%, p< 0.001). Visual aura lasting over an hour
(18.7 vs. 8.9%), hemisensory symptoms (99.0 vs.
38.3%, p< 0.001) and speech disturbances (88.6 vs.
32.1%, p< 0.001) were also more prevalent in HM
patients than in NHMwA patients. Furthermore,
basilar-type aura symptoms including bilateral sen-
sory symptoms, basilar vertigo, tinnitus, hypoacusia,
diplopia, swallowing diﬃculties, unconsciousness, and
confusion were more often reported by HM patients
than NHMwA patients (p< 0.001) (Figure 4). Almost
all evaluated non-migraine speciﬁc coexisting symp-
toms were similarly more common in HM patients
than in NHMwA patients, the only exceptions
being motion sickness and the swelling of eyelids
(Figure 4).
In addition to other clinical characteristics, HM
patients reported more psychological disorders (23.9
vs. 17.7%, p¼ 0.005), allergy (45.0 vs. 34.5%,
p< 0.001), asthma (12.7 vs. 9.4%, p¼ 0.049), and
Raynaud’s phenomenon (21.9 vs. 13.9%, p¼ 0.001)
than NHMwA patients. There were no signiﬁcant
diﬀerences in the prevalence of stroke, epilepsy, or dia-
betes (Figure 5). The reported prevalences are not
adjusted for age.
Visualisation of migraine symptom spectrum using
principal component analysis
To collectively visualize diverse migraine symptoms
and examine potential clustering of patients and
traits, we applied explorative PCA analysis to the
phenotype data. Eigenvalue distribution suggests
retaining only the ﬁrst principal component that alone
explains 49.8% of the variance among all inspected
symptoms. However, to assess any potential clustering,
we further visually investigated ﬁrst 10 components
that together explain 67.6% of all variance. None of
these 10 components seem to separate individuals into
distinguishable or pronounced groups. Rather, the dis-
tribution seems to be continuous across all inspected
components. For illustration, the ﬁrst two principal
components of 53 migraine symptom characteristics
across 2730 individuals are plotted in Figure 6, high-
lighting the variant carriers from Table 2. Most HM
patients seem to concentrate to the other end of the ﬁrst
component, which explains nearly half of the overall
Hiekkala et al. 1855
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symptom diversity (Figure 6). Component loadings for
these ﬁrst two components can be found in
Supplementary Figure 1. The correlation structure of
individual symptoms is illustrated in Supplementary
Figures 2 and 3.
Genetic findings
To study the involvement of CACNA1A, ATP1A2 and
SCN1A in the HM phenotype, we exome sequenced sam-
ples of 293 patients with HM from 243 Finnish migraine
families. We identiﬁed and validated 15 potentially
damaging, rare frequency variants (Figure 1, Table 1).
Eleven of the validated variants did not completely fulﬁll
our predetermined mutation criteria, whereas
c.1994C>T (p.Thr665Met) in CACNA1A,
c.1148G >A (p.Arg383His) and c.1816G>A
(p.Ala606Thr) in ATP1A2 were considered as causative
variants. Their pathogenicity is further supported by
their location in highly conserved amino acids and pre-
vious clinical and functional studies. In addition to the
three pathogenic missense variants, we identiﬁed one
probable causative frameshift variant
c.7501_7502delAG (p.Ser2501Ter) in CACNA1A.
The p.Thr665Met likely causal mutation in
CACNA1A was found in one family where it co-segre-
gates with the HM phenotype. However, the proband’s
elder sister, who does not have migraine, carries the
mutation, leading to a penetrance of 75% (Figure 7,
family A, II:2).
The other two likely causal mutations were located
in the ATP1A2 gene. The p.Ala606Thr was present in
one family co-segregating with the HM phenotype with
a complete penetrance. Three of the mutation carriers
have HM triggered by minor head trauma (Table 2).
Interestingly, both WES and Sanger sequencing data
conﬁrmed that the proband’s daughter does not carry
the mutation, even though she has HM based on the
ICHD-3 beta criteria (Figure 7, family B, III:1).
However, her symptoms are less severe: for instance,
she has motor weakness in the arm but not in the leg,
she was 30 years old when she had her ﬁrst migraine
attack, and her attacks are not triggered by minor head
trauma. Although her diagnosis could not be explained
0.6
0.4
0.2
0.0
1 2 3 4
PC1
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Figure 6. First two principal components of 53 migraine symptom characteristics across 2730 individuals. Hemiplegic migraine (HM)
patients seem to be at the other end of the spectrum but do not form a separate, bounded cluster. Variant carriers from four families
(A,B,C,D) are highlighted with squares. Family trees of A, B and C are presented in Figure 7. Family D is a large familial hemiplegic
migraine family with a previously identified mutation (p.Thr345Ala) in ATP1A2 gene (12).
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by the identiﬁed p.Ala606Thr variant, it could however
be caused by other genetic factors combined with envir-
onmental factors. For instance, she might have inher-
ited some still unknown genetic susceptibility factors
from her father, who has migraine with typical aura.
The p.Arg383His variant in family C (Figure 7) was
transmitted from an aﬀected father to daughter and
thus co-segregated with the HM phenotype. However,
three unaﬀected family members (III:1, II:3, II:7) also
carried the mutation. The proband’s brother (III:1) has
had one HM attack, and thus does not fulﬁll the IHS
criteria for FHM (Table 2). Two other family members
with the variant, but without HM, were over 40 years
of age when they participated in the study (Table 2).
Thus, it is unlikely that they would develop HM in later
life. From those ﬁve family members with the
p.Arg383His mutation, only two have an FHM diag-
nosis, corresponding to a 40% penetrance.
Furthermore, we identiﬁed one probably causal
frameshift variant, p.Ser2501Ter, in the CACNA1A
gene in two SHM individuals (Figure 8). The other
patient has three relatives carrying the same variant
and having diverse migraine symptoms, not fulﬁlling
the HM criteria (Figure 8; Family E II:1, II:3, III:3).
The variant is extremely rare in the gnomAD database
(Table 1) and it is located in the last exon of the gene,
where it creates a premature stop codon. Thus, in the
protein level, the ﬁve last amino acids forming the end
of the C-terminal region of the channel are missing.
Discussion
The present study describes one of the largest hemiplegic
migraine samples screened for mutations in CACNA1A,
ATP1A2 and SCN1A, and shows that HM patients do
not seem to form a clearly separate group of their own,
in relation to general migraine and aura symptoms, but
rather reﬂect an extreme phenotype in the migraine with
aura continuum. Only 7% (3/44) of the studied Finnish
FHM families and none of the studied 201 SHM
patients have likely damaging exonic mutations in the
known three FHM genes.
Family A (CACNA1A, c.1994C>T, p. Thr665Met) Family B (ATP1A2, c.1816G>A, p.Ala6060Thr)
Family C (ATP1A2, c.1148G>A, p.Arg383His)
I:1
No headache
–/–
II:1
No headache
–/–
II:2
No headache
+/–
II:3
MwA+MwoA
–/–
III:2
MwA+MwoA
–/–
II:9
MwA+MwoA
–/–
III:8
MwA+MwoA
–/–
III:6
MwA+MwoA
–/–
III:7
Headache
–/–
P P
P
I:2
   Hemiplegic migraine
+/–
II:4
Hemiplegic migraine
+/–
III:1
Hemiplegic migraine
+/–
II:5
No headache
–/–
II:1
MwA+Headache
–/–
II:3
No Headache
–/–
II:4
No+Headache
–/–
II:2
MwA+MwoA+HM
+/–
III:4
MwA+MwoA
–/–
IV:2
MwA+MwoA
–/–
III:3
MwA+MwoA+HM
–/–
IV:3
MwA+MwoA+HM
+/–
IV:4
MwA+Probable migraine+HM
+/–
II:8
MwA+Probable migraine
–/–
III:5
Probable migraine
–/–
II:1
MwA+Probable migraine+HM
+/–
III:1
MwA+Probable migraine
+/–
III:1
MwA+MwoA+HM
–/–
II:4
MwA+MwoA
–/–
IV:1
MwoA
–/–
IV:2
No Headache
–/–
II:5
No Headache
–/–
II:6
No Headache
–/–
II:7
No Headache
+/–
II:2
No Headache
–/–
IV:1
No Headache
–/–
III:2
No Headache
–/–
II:3
MwoA
+/–
III:2
MwA+MwoA+HM
+/–
I:1
I:1 I:2
I:2
III:3
HM= Hemiplegic migraine
MwA+MwoA = Migraine with and without aura
MwA = Migraine with aura
MwA = Migraine without aura
Male Female
Figure 7. Pedigrees of the Finnish familial hemiplegic migraine families with mutations in the CACNA1A and ATP1A2 genes. Mutation is
indicated withþ and wild type allele with ; reference sequences: ENST00000361216.3 (ATP1A2), ENST00000360228.5 (CACNA1A).
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Hemiplegic migraine is a clinically
heterogeneous disease
HM patients reported more often severe and long lasting
headache with extended aura episodes than NHMwA
patients. They also had a higher proportion of attacks
with visual aura symptoms and earlier age of headache
onset compared to NHMwA patients. Thus, our clinical
results are in line with the previously published results
from Danish population-based studies (2,20).
In addition to other clinical characteristics, we found
diﬀerences in the prevalences of self-reported psychi-
atric disorders, asthma, and Raynaud’s phenomenon
between the HM and NHMwA groups. There were
no signiﬁcant diﬀerences in prevalences of self-reported
epilepsy and stroke between these groups. The preva-
lences seen in our study for epilepsy, diabetes and
asthma are similar to prevalences reported for migraine
with aura in a large population-based Danish study
(21). However, the prevalence for stroke, which was
not age-adjusted, was higher than in the Danish data
(8.7% vs 1.7%).
Most HM patients had a positive family history for
common forms of migraine. A notable proportion of
SHM families (43%) had more than three family mem-
bers with migraine with or without aura. The propor-
tion was even higher in FHM families (78%). In some
families, there were two SHM patients who were third-
or greater-degree relatives. From this perspective, the
distinction between SHM and FHM is ambiguous and
might suggest that the genetic and overall pathogenic
background is overlapping.
CACNA1A, ATP1A2 and SCN1A causative
variants are present in only a small proportion of
the hemiplegic migraine patients
Surprisingly, our results showed that only 7% (3/44) of
the studied Finnish FHM families and none of the
studied 201 SHM patients have exonic mutations in
the known FHM genes. The percentage is lower,
although of the same order of magnitude, than previ-
ously reported. The Danish population based studies
showed that 14% of the studied FHM families (6/42)
had mutations in the CACNA1A or ATP1A2 genes (6),
and that these genes were not the major cause of SHM
in a sample of 105 patients (7). Even though we did not
identify any deﬁnitive FHM mutations in SHM
patients, there are other studies supporting their role
also in SHM (8). Patients with early-onset SHM asso-
ciated with neurological symptoms are especially at
high risk of carrying a causal mutation in CACNA1A
or ATP1A2 (22).
One possible explanation for the lower percentage of
mutation carriers compared to the Danish studies might
be the selection process of patients. In the Finnish
Migraine Genome Project, we have not speciﬁcally
tried to recruit patients with HM but rather patients
with all migraine subtypes. At the beginning of the pro-
ject, we were focusing on migraine with aura families
and, later on, families with all migraine subtypes.
Another explanation could be our strict mutation cri-
teria. In this study, we utilized large allele frequency data-
bases and considered the identiﬁed variant as pathogenic
only if the follow up analyses supported the conclusion.
Three identified pathogenic variants
All three pathogenic variants identiﬁed in this study
have been described earlier, including supporting func-
tional data on their damaging role. The p.Thr665Met is
the most reported mutation in CACNA1A causing HM
(3). The p.Ala606Thr is also a previously reported
mutation (23) with functional data suggesting a loss
of function eﬀect (24). In our study, carriers of this
mutation had a severe phenotype including FHM
attacks triggered by minor head trauma and early age
at onset of migraine (<14 year olds).
Family E (CACNA1A, c.7501_7502delAG, p.Ser2501Ter) Family F (CACNA1A, c.7501_7502delAG, p.Ser2501Ter)
I:1 I:2I:1
P
I:2
HM= Hemiplegic migraine
MwA+MwoA = Migraine with and without aura
MwA = Migraine with aura
MwA = Migraine without aura
Male Female
II:1
MwA+MwoA+HM
+/–
III:1
MwA+MwoA+HM
+/–
III:3
MwoA
+/–
III:2
MwoA
–/–
II:4
Headache
–/–
II:3
Probable migraine
+/–
II:1
Probable migraine
cluster headache
+/–
II:2
No headache
–/–
Figure 8. Pedigrees of the Finnish hemiplegic migraine families with frameshift variant in the CACNA1A gene. Mutation allele is
indicated withþ and wild type allele with ; reference sequence: ENST00000360228.5 (CACNA1A).
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The penetrance of p.Thr665Met and p.Ala606Thr in
our families is comparable to the previous reports on
CACNA1A and ATP1A2 mutations (80–90%) (23,25).
However, the penetrance of p.Arg383His is signiﬁcantly
lower, only 40% in this study, and the symptoms of
the aﬀected carriers are less severe. For instance, one
of the carriers with HM reported experiencing his ﬁrst
migraine attack at the age of 27. He also reported mild
headache intensity and 10–50 HM attacks at the age of
73 with short duration of hemiplegia (15 minutes).
However, previous genetic and functional evidence
(24,26), the very low population allele frequency
and location in a highly conservative site all support
the conclusion that p.Arg383His is also a true disease-
causing variant.
In general, based on our observational results, clin-
ical features of the patients with the identiﬁed causative
variants are not clearly diﬀerent from the other studied
HM patients. They have a similar positive family load
of common migraine and their attacks are severe, but
not particularly more severe than the rest of the HM
group. Because none of the identiﬁed mutations alone
explain the observed clinical heterogeneity, this sug-
gests that there are other genetic and/or environmental
susceptibility factors for migraine in these families.
One probably causal variant in CACNA1A
Moreover, we identiﬁed one probably causal,
extremely rare, frameshift variant (p.Ser2501Ter) in
the CACNA1A gene. The variant creates a premature
stop codon deleting the last ﬁve amino acids. The loca-
tion in the very end of the transcript might make the
deletion less damaging, but alternatively it might also
protect the transcript from nonsense-mediated mRNA
decay. Furthermore, the C-terminus of CaV2.1 a1A
subunit is known to have a role in the regulation
of the channel activity by participating in a number
of protein–protein interactions (27). Interestingly, the
very end of the C-terminal region contains a conserved
DDWC-COOH (D2503-C2506) binding motif for the
neuronal adaptor protein Mint1 (28). Lack of func-
tional studies or more extensive genetic data makes
interpreting the pathogenicity of this variant challen-
ging, and thus additional reported HM patients and
functional evidence is needed.
Likely benign variants
Four SCN1A variants (p.Arg1928Gly, p.Thr1250Met,
p.Thr1174Ser, p.Arg542Gln) found in our study, previ-
ously reported in epilepsy or FHM3 (29–32), did not
fulﬁll our predetermined mutation criteria, and thus
were not classiﬁed as causative variants. Our strict
mutation criteria are supported by a recent study
re-evaluating the pathogenicity of SCN1A variants in
common epilepsies and concluding that they are likely
benign (33).
The p.Ala453Thr variant in CACNA1A has been sug-
gested to be a negative modiﬁer of the migraine aura
phenotype, protecting its carriers from FHM in a
migraine with aura family (34). Since the variant was
identiﬁed in 12 of our families with HM and did not
completely fulﬁll our predetermined mutation criteria, it
was not considered here either as protective or causative.
Strengths and limitations
The main strength of this study is the large and well-
characterized migraine family sample. Our study is
part of the Finnish Migraine Genome Project, now con-
sisting of over 2400 families and 10,500 individuals,
which is, to our knowledge, the largest migraine family
collection in the world. Even though our sample collec-
tion is not population based, the participants come from
all geographical regions of Finland.
Because of the large number of participants, migraine
phenotype data has been collected with a combination of
individual interviews and with the extensive, validated
Finnish Migraine Speciﬁc Questionnaire for Family
Studies (9). The questionnaire is validated to diagnose
migraine with aura and migraine without aura, but not
speciﬁcally for hemiplegic migraine. To overcome this
limitation, the participants were asked to give a precise
description of hemiplegia during the attack, and in case
of uncertainty the neurologist conﬁrmed the diagnosis
by phone.
Although questionnaire-based studies provide a
number of advantages, it is also important to recognize
that the self-reported data has its own limitations and is
not equivalent to data derived from face-to-face inter-
views by headache experts. However, since the clinical
information has been collected using identical methods
regardless of the diagnostic subgroup, the same limita-
tions apply to all patients, making the data comparable.
A low or unbalanced response rate causes non-
response bias, thus decreasing the reliability of the
speciﬁc comparison. In the present study, most of
the questions had a high response rate (>80%), but
there were also some questions with response rates
lower than 60%. When comparing subgroups, the
response rate in HM was somewhat higher than in
the NHMwA group. The lower response rates for spe-
ciﬁc questions can be explained by our lengthy, exten-
sive, and thematically structured paper questionnaire.
If the respondent does not have the speciﬁc symptom or
is uncertain about it, the question might be left unan-
swered. These factors might explain the lower response
rate in the NHMwA group compared to the HM
group. Our overall interpretation is that, when
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considering both the answers and the response rates,
migraine has a greater impact on patients with HM
compared to the patients with NHMwA. While the
non-response bias has to be acknowledged, it should
not inﬂuence the validity of the presented conclusions
in a study of this scale and scope.
Due to the unique population structure of Finland,
there is signiﬁcantly less genetic variation compared to
more mixed populations, especially in the rare and low
allele frequencies. On the other hand, the rare and low
frequency variants that are present are often enriched in
the population (35). Since the Finnish population is a
powerful resource for identifying disease-associated
genetic variants, we expected to ﬁnd new mutations in
the FHM genes that would be speciﬁc to the Finnish
population. However, this was not the case, since all the
mutations identiﬁed in this study have been reported
earlier in other European populations.
Future prospects
The fact that only 7% of the Finnish FHM families
have likely causal mutations in the known FHM
genes supports the hypothesis that there must be
additional variants contributing to the HM phenotype.
It is possible that causal mutations may locate in
the noncoding regions of the known FHM genes, but
it also suggests that there are additional genes contri-
buting to the HM phenotype. Sequencing techniques
might reveal rare and large eﬀect variants in some
new migraine genes, especially in families with several
aﬀected individuals.
An alternative hypothesis is that HM might not
be a true monogenic disease, but a polygenic disease
where common variants (36) contribute to the disease
outcome. The familial load of migraine with and with-
out aura, and the observation that HM patients
do not cluster as a separate group, but rather have
similar aura and headache characteristics to the
patients with less severe phenotypes, suggest that
there might be a shared genetic basis for all migraine
subtypes. We speculate that, at least in some cases,
this general genetic migraine load combined with add-
itional genetic and environmental risk factors could
cause the more severe attacks that the HM patients
experience.
Article highlights
. The results of the study highlight HM as a clinically and genetically heterogeneous disease.
. Based on patterns of clinical presentation, HM patients do not seem to form a clearly separate group of their
own, in relation to general migraine and aura symptoms, but rather reﬂect an extreme phenotype in the
migraine with aura continuum.
. Our study showed that only 7% of the Finnish familial hemiplegic migraine families have exonic mutations
in CACNA1A, ATP1A2 and SCN1A genes, suggesting that there are additional genetic factors contributing
to the HM phenotype.
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